The Claim
In overweight/obese adults, a 12-week regimen of once-weekly semaglutide combined with lifestyle intervention is associated with improvements in multiple metabolic parameters, including reductions in HbA1c, alanine aminotransferase, aspartate aminotransferase, uric acid, and total cholesterol.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Overweight or obese adults who take semaglutide once a week and follow a lifestyle program for 12 weeks show improvements in several health markers, such as lower blood sugar, better liver enzymes, reduced uric acid, and lower total cholesterol.
See the scientific wording
In overweight/obese adults, a 12-week regimen of once-weekly semaglutide plus lifestyle intervention is associated with improvements in multiple metabolic parameters, including reductions in HbA1c (-0.44%), alanine aminotransferase (-15.07 U/L), aspartate aminotransferase (-8.59 U/L), uric acid (-43.61 μmol/L), and total cholesterol (-0.30 mmol/L) (all P < 0.001 after Bonferroni correction).
Semaglutide reduces appetite, leading to weight loss mainly from belly fat. Losing belly fat lowers fat in the liver, improves how the body uses sugar, reduces uric acid, and lowers cholesterol.
What the research says
1 studyStudy: Effects of once-weekly semaglutide on regional body composition in overweight or obese adults
The study found that overweight people taking semaglutide and changing their lifestyle for 12 weeks had better health markers like blood sugar, liver enzymes, and cholesterol, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.